Clinical Trials on Healthy Participants With Moderate and High Cardiovascular Risk in South Africa

Total 16 results

North-West University, South Africa
GlaxoSmithKline; Novartis; Pfizer; Boehringer Ingelheim; Medical Research Council; Medical... and other collaborators

Active, not recruiting

The African-PREDICT Study (PREDICT)

Cardiovascular Diseases | Hypertension | Health Risk Behaviors | Arterial Stiffness | Young | Renin Hypertension

South Africa
Bayer

Completed

A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease (ARRIVE)

Moderate Risk of CVD

Poland, United States, Italy, United Kingdom, Germany, Spain, Puerto Rico, Ireland
Novartis Pharmaceuticals

Terminated

Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations. (ReTHINK)

Myelofibrosis With High Molecular Risk Mutations

Belgium, Spain, United Kingdom, Hungary, Italy, Japan, Taiwan, Germany, Canada, Singapore, Austria, Australia, France, Israel, Sweden, Switzerland, Hong Kong, Greece, Turkey, Brazil, Russian Federation, Denmark, Portugal, Norway, Poland
Alnylam Pharmaceuticals

Recruiting

Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) (KARDIA-3)

Hypertension | High Cardiovascular Risk

United States, Canada
University of the West of Scotland
Swansea University

Completed

The Influence of a High Intensity Physical Activity Intervention on a Selection of Health Related Outcomes: An Ecological Approach

To Assess the Impact of the HIT Intervention on Physiological Responses | To Assess the Role of a Secondary High School as a Setting for Promoting Healthy Eating and PA Behaviours | To Determine the Associations Between CVD Risk Factors at Baseline in 15 - 18 Year Old Youth

United Kingdom
Biosensors Europe SA

Active, not recruiting

LEADERS FREE II: BioFreedom™ Pivotal Study

Acute Coronary Syndrome | High Bleeding Risk

United States, Canada, France, Italy, United Kingdom, Germany, Denmark
AstraZeneca
The Cleveland Clinic; IQVIA RDS Inc.

Completed

Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia (STRENGTH)

Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)

United States, Belgium, Italy, Netherlands, Denmark, Taiwan, Poland, Russian Federation, Korea, Republic of, Hungary, United Kingdom, China, New Zealand, Czechia, Australia, South Africa, Ukraine, Japan, Canada, Mexico, Lithuania, Estoni...
Omar Nadeem, MD
Janssen, LP

Recruiting

DARA RVD For High Risk SMM (PRISM)

Multiple Myeloma | High-risk Smoldering Multiple Myeloma

United States
AstraZeneca

Completed

Prevalence of Peripheral Arterial Disease in Subject With a Moderate Risk of Cardiovascular (CV) Disease (CVD) in Primary Prevention (PANDORA)

Peripheral Arterial Disease (PAD) | Moderate Risk for Cardiovascular Disease (CVD)

France, Netherlands, Switzerland, Greece, Belgium, Italy
Eisai Inc.
Thrombolysis In Myocardial Infarction (TIMI) Academic Research Organization

Completed

A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors (CAMELLIA-TIMI)

Obesity | Cardiovascular Disease | Overweight | Type 2 Diabetes | High Cardiovascular Risk

United States, Canada, Poland, Australia, Mexico, New Zealand, Bahamas, Chile
Impulse Dynamics

Recruiting

Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer)

Heart Failure | Heart Failure With Preserved Ejection Fraction | Diastolic Heart Failure | Heart Failure With Mid Range Ejection Fraction | Heart Failure With Moderately Reduced Ejection Fraction

United States
Population Health Research Institute
Canadian Institutes of Health Research (CIHR); Heart and Stroke Foundation...

Recruiting

Prospective Urban Rural Epidemiology Study (PURE)

Cardiovascular Diseases | Lung Diseases | Cancer | Risk Factor, Cardiovascular | Health Behavior | Injuries | Environmental Exposure | Renal Disease | Communicable Disease

India, Saudi Arabia, Iran, Islamic Republic of, Peru, Pakistan, Argentina, Bangladesh, Brazil, Canada, Chile, China, Colombia, Kazakhstan, Kyrgyzstan, Malaysia, Palestinian Territory, occupied, Philippines, Poland, Russian Federation and more
AstraZeneca
Bristol-Myers Squibb; Hadassah Medical Organization; The TIMI Study Group

Completed

Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events (DECLARE-TIMI58)

Diabetes Mellitus, Non-Insulin-Dependent | High Risk for Cardiovascular Event

United States, Canada, France, Italy, Netherlands, Spain, Belgium, Thailand, Vietnam, Bulgaria, Korea, Republic of, Brazil, Philippines, Russian Federation, Turkey, Taiwan, Australia, Israel, South Africa, Germany, Japan, Czechia, H... and more
Janssen Research & Development, LLC

Completed

A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

High-risk Smoldering Multiple Myeloma

United States, United Kingdom, Belgium, Germany, France, Spain, Korea, Republic of, Australia, Israel, Greece, Sweden
Bayer

Recruiting

A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke (OCEANIC-STROKE)

Acute Non-cardioembolic Ischemic Stroke | Prevention of Ischemic Stroke | High-risk Transient Ischemic Attack

United States, Switzerland, Belgium, Sweden, Canada, Australia, Taiwan, Spain, Korea, Republic of, Latvia, Israel, Malaysia, Greece, Japan, Turkey, Netherlands, Romania, China, United Kingdom, Portugal, Italy, Brazil, France, Slovakia, ... and more
National Cancer Institute (NCI)

Recruiting

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

Lymphoplasmacytic Lymphoma | Ann Arbor Stage III Diffuse Large B-Cell Lymphoma | Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Grade 3b Follicular... and other conditions

United States

Clinical Trials on Healthy Participants With Moderate and High Cardiovascular Risk in South Africa

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gabon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations